No Data
No Data
Piper Sandler Maintains Poseida Therapeutics(PSTX.US) With Hold Rating, Maintains Target Price $10
Piper Sandler Downgrades Poseida Therapeutics(PSTX.US) to Hold Rating, Maintains Target Price $10
Roche's Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial Uncertainties
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
Key Deals This Week: EnLink Midstream, Peabody, StoneCo, UniCredit and More
10 Health Care Stocks With Whale Alerts In Today's Session
Ryand83 OP : it's Christmas shopping time for Bios. I'm expecting more under the radar announcements over the next few weeks.
Ryand83 OP : ^^ @BadPaint @Tatae2023